Opinion - How many drug targets are there?
Opinion - How many drug targets are there?
复制标题
DOI：
10.1038/nrd2199
复制
发表时间：
2006-12-01
影响因子：
120.1
通讯作者：
Hopkins, Andrew L.
中科院分区：
文献类型：
--
作者：
Overington, John P.;Al-Lazikani, Bissan;Hopkins, Andrew L.
在过去的十年中，批准药物的分子靶点数量一直存在争议。在这里，我们调和明显矛盾的以前的报告到一个全面的调查，并提出了一个共识的数量目前的药物靶点的所有类别的批准的治疗药物。一个显著的特点是靶点创新的历史速率（针对新靶点的药物上市的速率）相对恒定;然而，针对新家族的药物开发速率要低得多。最近批准的靶向蛋白激酶的药物突出了另外两个趋势：对多药理学重要性的认识，以及基因家族主导的方法在产生新的重要疗法方面的力量。
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation ( the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.